Other

Roche to pay $7.1 bn for Telavant Holdings

Swiss pharmaceutical group Roche said Monday it will pay $7.1 billion to buy Telavant Holdings, a group developing new treatments for inflammatory bowel diseases.

Medical research

Deep dive into the gut unlocks new disease treatments

The more diverse species in your gut, the better it is for your health. Now an international team led by the Hudson Institute of Medical Research has found a way to determine which species are important and how they interact ...

Immunology

Immune cells identified as 'metabolic factories' in the gut

A research team from MedUni Vienna has now demonstrated for the first time the central role of macrophages in the renewal of intestinal cells, which sheds light on the complex interplay between immune cells and tissue regeneration. ...

page 6 from 40